189 related articles for article (PubMed ID: 18612274)
1. 2 billion euro IMI launched with European pharma.
Hodgson J
Nat Biotechnol; 2008 Jul; 26(7):717-8. PubMed ID: 18612274
[No Abstract] [Full Text] [Related]
2. Mixed scores for European research.
Chipman A
Nature; 2007 Nov; 450(7166):16-7. PubMed ID: 17972849
[No Abstract] [Full Text] [Related]
3. Payers growing influence on R&D decision making.
Hughes B
Nat Rev Drug Discov; 2008 Nov; 7(11):876-8. PubMed ID: 18974741
[No Abstract] [Full Text] [Related]
4. Overcoming the challenges in the pharma/biotech industry.
Graul AI; Prous JR
Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
[TBL] [Abstract][Full Text] [Related]
5. Impossible fixes.
Nat Biotechnol; 2010 Feb; 28(2):103. PubMed ID: 20139925
[No Abstract] [Full Text] [Related]
6. Overcoming further challenges in the pharma/biotech industry: 2007 update.
Graul AI; Cruces E; Revel L; Serradell N; Rosa E
Drug News Perspect; 2008; 21(1):44-58. PubMed ID: 18301809
[TBL] [Abstract][Full Text] [Related]
7. Diabetes research investment in the European Union.
Halban PA; Ferrannini E; Nerup J
Nat Med; 2006 Jan; 12(1):70-2. PubMed ID: 16397573
[No Abstract] [Full Text] [Related]
8. How should we support pharmaceutical innovation?
Grootendorst P
Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):313-20. PubMed ID: 19670991
[TBL] [Abstract][Full Text] [Related]
9. Brexit and research: goodbye EU money and colleagues?
Gannon F
EMBO Rep; 2016 Sep; 17(9):1237-8. PubMed ID: 27466322
[TBL] [Abstract][Full Text] [Related]
10. Scientific funding. Is €80 billion on the horizon for European research?
Reardon S
Science; 2011 Dec; 334(6061):1331-3. PubMed ID: 22158789
[No Abstract] [Full Text] [Related]
11. Members need only apply.
Nat Biotechnol; 2011 Jul; 29(7):551. PubMed ID: 21747362
[No Abstract] [Full Text] [Related]
12. New EU antitrust law burdens licensing.
Louët S
Nat Biotechnol; 2004 Jun; 22(6):643. PubMed ID: 15175670
[No Abstract] [Full Text] [Related]
13. Devil in the details.
Nat Med; 2008 Feb; 14(2):105-6. PubMed ID: 18256601
[No Abstract] [Full Text] [Related]
14. Eurofile. Private-public drive to cut delays in drug development.
Mundell I
Eur J Cancer; 2008 Jan; 44(2):169. PubMed ID: 18335586
[No Abstract] [Full Text] [Related]
15. Drug development for children: how is pharma tackling an unmet need?
Hawcutt DB; Smyth RL
IDrugs; 2008 Jul; 11(7):502-7. PubMed ID: 18600597
[TBL] [Abstract][Full Text] [Related]
16. Europe fiddles while innovation burns.
Frantz S
Nat Rev Drug Discov; 2005 Sep; 4(9):704-5. PubMed ID: 16178115
[No Abstract] [Full Text] [Related]
17. Europe's arrested development.
Nature; 2006 Oct; 443(7114):883. PubMed ID: 17065991
[No Abstract] [Full Text] [Related]
18. European research. Unprecedented budget increase draws faint praise.
Enserink M
Science; 2006 Dec; 314(5805):1523-5. PubMed ID: 17158294
[No Abstract] [Full Text] [Related]
19. European competition.
Nat Mater; 2006 Nov; 5(11):839. PubMed ID: 17077838
[No Abstract] [Full Text] [Related]
20. Pharmaceutical price differences in the EU: investigation from cardiovascular disease drugs.
Timur A; Picone G
Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):251-6. PubMed ID: 19527097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
